Europe Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$390.8 MnPlaceholder estimate
Estimate 2025$463.5 Mn16.1% of the global market
Projected 2034$2.15 Bn 364.3%Adds $1.69 Bn over 9 forecast years
CAGR 2025–203418.6%Faster than 87% of 180 Pharmaceuticals markets here
Key players4
Europe is 16.09% of the global market.
Among regions, the largest is North America at $1.48 Bn.
16 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Long-Acting HIV Treatment Market Analysis Executive Summary
Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.
Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).
Europe Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Long-Acting HIV Treatment Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.
Competitive Landscape for Long-Acting HIV Treatment Market in Europe
The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in Europe
Long-Acting HIV Treatment in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], CBG-MEB (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15] ClinicalTrials.gov lists 16 studies on Long-Acting HIV Treatment that are recruiting, active or about to start in Europe.[16]
[16]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Use
4.2 By Drug
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 ViiV Healthcare
7.2 Gilead Sciences
7.3 Johnson & Johnson
7.4 Merck & Co.
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The long-Acting HIV Treatment market can be segmented based on various criteria, including use, drug and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Long-Acting HIV Treatment market in Europe?
Placeholder estimate: about $463.5 Mn in 2025, rising to about $2.15 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Europe growing?
Placeholder estimate: about 18.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Long-Acting HIV Treatment are running in Europe?
16 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Long-Acting HIV Treatment?
PubMed lists 17 papers on Long-Acting HIV Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.